Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside

Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), equivalent to 14.6% of the common stock.

Peter Kolchinsky

In another filing the fund revealed that of 2.43 million shares, 1.43 million shares were obtained via conversion from Series C preferred stock, held by Ra Capital prior to the company’s IPO. At the same time, the fund purchased a total of 1.0 million shares at a price of $15 apiece. Peter Kolchinsky is a director of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), and he might exercise his control received from this position.

Yesterday, James E. Flynn’s Deerfield Management, disclosed holding 2.42 million common shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). James Flynn is a large shareholder at Dicerna. In another filing Brookside Capital, managed by Bain Capital also revealed that it holds 2.34 million shares of the company.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), is a biopharmaceutical company, and treats rare inherited diseases in liver and for cancer. The company went public a couple of days ago, offering 6.0 million shares at a price of $14.0 per share.

The stock has been favored amongst insiders Stephen Hoffman, director at Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), purchased 200,000 shares from the IPO, and currently owns around 1.73 million shares.

RA Capital Management invests in companies with promising drugs and technologies. A day before the fund revealed in a filing that it initiated a stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX), and now holds 750,000 shares.

At the end of September 2013, RA Capital Management held 10.42 million shares of Dyax Corp. (NASDAQ:DYAX), with 7.45% of its equity portfolio invested in the company’s stock.

Disclosure: none

Recommended Reading:

Diamond Hill Capital Management Top Picks: United Technologies Corp. (UTX), American International Group Inc. (AIG) & More

Deerfield Management Reports New Stake in KaloBios Pharmaceuticals Inc (KBIO)

Hedge Fund Highlights: Warren Buffett, Bill Ackman & Richard Gerson

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!